Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Low-Dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection After Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders - A Multi-Center Trial

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00397813
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:25.235172+00:00
Published At
2018-10-24T00:00:00+00:00
Record Updated At
2020-01-31
Results Posted At
2018-10-24
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Chronic Myelomonocytic Leukemia", "de Novo Myelodysplastic Syndrome", "Essential Thrombocythemia", "Myeloproliferative Neoplasm", "Paroxysmal Nocturnal Hemoglobinuria", "Polycythemia Vera", "Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase", "Primary Myelofibrosis", "Refractory Anemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Ring Sideroblasts", "Refractory Cytopenia With Multilineage Dysplasia", "Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2020-01-31"
protocolSection.identificationModule.nctId
"NCT00397813"
protocolSection.identificationModule.officialTitle
"Low-Dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection After Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders - A Multi-Center Trial"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2018-10-24"

Study condition terms

  • Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative (protocolSection.conditionsModule.conditions)
  • Chronic Myelomonocytic Leukemia (protocolSection.conditionsModule.conditions)
  • de Novo Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
  • Essential Thrombocythemia (protocolSection.conditionsModule.conditions)
  • Myeloproliferative Neoplasm (protocolSection.conditionsModule.conditions)
  • Paroxysmal Nocturnal Hemoglobinuria (protocolSection.conditionsModule.conditions)
  • Polycythemia Vera (protocolSection.conditionsModule.conditions)
  • Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase (protocolSection.conditionsModule.conditions)
  • Primary Myelofibrosis (protocolSection.conditionsModule.conditions)
  • Refractory Anemia (protocolSection.conditionsModule.conditions)
  • Refractory Anemia With Excess Blasts (protocolSection.conditionsModule.conditions)
  • Refractory Anemia With Ring Sideroblasts (protocolSection.conditionsModule.conditions)
  • Refractory Cytopenia With Multilineage Dysplasia (protocolSection.conditionsModule.conditions)
  • Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.